What moksha8 Pharmaceuticals does

Moksha8 Pharmaceuticals is a privately held US pharmaceutical company founded in 2007 and headquartered in Wayne, Pennsylvania, focused on developing therapeutics for central nervous system (CNS) and mental health disorders. The company operates in a therapeutic area characterized by complex regulatory pathways, significant unmet medical need, and high barriers to clinical entry, with a workforce of 501-1000 employees consistent with a clinical-to-commercial stage specialty pharmaceutical developer.\n\nThe company's capital base has been built through approximately $224 million of disclosed equity raised across five rounds from 2008 through 2012, with strategic investors Forest Laboratories (October 2012, $125M lead), Watson Pharmaceuticals (October 2010, $30M Series 3 lead), TPG Biotech (June 2008, $39M Series 2 lead), and Montreux Equity Partners (December 2009, $25M Series 2 lead). The Forest Laboratories and Watson Pharmaceuticals investments are notable as strategic corporate capital from larger pharmaceutical firms, which historically have signaled both asset validation and a likely commercial pathway via licensing, co-development, or acquisition.\n\nLeadership is anchored by founder Simba Gill as President and Chief Executive Officer, with Stig Pedersen serving as Executive Chairman. Public commercial details — specific product portfolio, approved indications, branded revenue mechanics, and current-period financials — are not present in the available input, suggesting the company operates primarily behind confidential B2B licensing and development arrangements typical of pre-commercial or early-commercial specialty CNS biotechs.

Name

moksha8 Pharmaceuticals

Legal name

Acino Latinoamericana S.A.

Website

https://moksha8.com

Company type

Private

Founded year

2007

Operating status

Operating

Headcount range

501–1,000 employees

Short description

Moksha8 Pharmaceuticals is a private US pharmaceutical company founded in 2007 and based in Wayne, Pennsylvania, developing therapeutics for central nervous system and mental health disorders.

Ownership category

akta.pro rank

Product category

Specialty Pharmaceuticals (CNS/Mental Health)

NAICS

Pharmaceutical Preparation Manufacturing (325412), Pharmaceutical and Medicine Manufacturing (3254)

SIC

Pharmaceutical Preparations (2834)

akta.pro primary industry

Neurology & CNS Specialty Pharmaceuticals (HLAIACAC)

akta.pro secondary industry

Neurology & Psychiatry (CNS) Pharmaceuticals (HLAIAAAF)

Keywords

• Central nervous system therapeutics
• Mental health pharmaceuticals
• CNS drug development
• Psychiatric medications
• Specialty pharmaceuticals

Headquarters

HQ city

Wayne

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Supply Chain, Operations, Marketing or Sales

Revenue model

1. Pharmaceutical product sales: Acino Latam markets and distributes innovative and proven medicines across Latin America, serving as a pharmaceutical partner in the region.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels2 records

Core offering

Moksha8 Pharmaceuticals is a specialty pharmaceutical company that develops and commercializes therapeutics for the treatment of central nervous system (CNS) and mental health disorders. The company focuses on bringing products to market that address unmet medical needs in neurology and psychiatry.

Product overview

Acino Latam operates as a pharmaceutical company in Latin America, serving as a partner for innovative and proven medicines. The company operates under the Arcera umbrella and offers services including partnership programs and marketing services for pharmaceutical products across the Latin American region. The product portfolio includes branded pharmaceutical products such as NABOTA® and Ultraproct LDO, distributed through their market channel.

Differentiator

Problem solved

Functional benefit

Brands

• NABOTA: Pharmaceutical product referenced in market announcement regarding packaging update

Segments1 record

Ideal customer profiles1 record

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Partnerships

One partnership is on record.

• ArceracoreStrategic or Co-development PartnerAcino Latam is part of Arcera, a parent pharmaceutical company providing strategic direction and portfolio of innovative and proven medicines for the Latin American market.

Scale indicators1 record

Recent moves5 records

Expansion highlights3 records

Broad incumbents

• Teva Pharmaceutical Industries: Large global pharmaceutical company with a significant CNS specialty franchise alongside generics. Comparable to Moksha8 in CNS therapeutic area, but at much greater scale and broader portfolio.
• AbbVie (acquirer of Forest Laboratories): Large global pharma that acquired Moksha8 strategic investor Forest Laboratories. Comparable as a major branded CNS player and counterparty to Moksha8.
• Lundbeck: Global CNS-focused pharmaceutical company with broad neurology and psychiatry portfolio. Comparable to Moksha8 as a major established CNS player.

Direct peers

• Neurocrine Biosciences: Pure-play CNS specialty pharma focused on neurology, psychiatry, and women's health. Closely comparable therapeutic-area focus to Moksha8.
• Jazz Pharmaceuticals: Specialty pharma with a meaningful CNS franchise (Xywav, Epidiolex, Sunosi) plus other therapeutic areas. Comparable to Moksha8 as a branded specialty pharma operating in neurology/psychiatry.
• Supernus Pharmaceuticals: Specialty pharmaceutical company focused on CNS disorders, including epilepsy, ADHD, and Parkinson's. Highly comparable to Moksha8 as a mid-sized branded CNS specialty pharma with a similar product-and-marketing profile.
• Acadia Pharmaceuticals: Specialty pharma focused on CNS disorders, with a commercial CNS product portfolio. Directly comparable to Moksha8 in therapeutic-area focus and specialty commercial model.

Emerging players

• Tonix Pharmaceuticals: Smaller CNS-focused specialty pharma developing therapeutics for CNS disorders, including migraine and psychiatry. Comparable to Moksha8 in therapeutic focus, though at a smaller scale.

Others

• Watson Pharmaceuticals (now Actavis/Allergan/AbbVie generics unit): Former strategic investor in Moksha8; now part of the AbbVie/Allergan generics franchise. Relevant as prior capital partner with deep familiarity with Moksha8.
• Acino (parent of Acino Latam): Swiss pharmaceutical company operating Acino Latam; partner/distribution counterparty in Latin America for Moksha8-aligned products. Relevant as ecosystem/regional distribution peer.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat3 records

Key risks6 records

Key highlights6 records

Customer concentration

• Xx.com/Moksha8
• YouTubeyoutube.com/@acinoswiss
• Facebookfacebook.com/acino.swiss
• LinkedInlinkedin.com/company/moksha8
• Instagraminstagram.com/acino.swiss

Revenue estimate

Valuation estimate

Number of profiles

Profiles2 records

Funding overview

Funding rounds5 records

Investors4 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about moksha8 Pharmaceuticals